- Home
- GEG vs CLNN Comparison
GEG vs CLNN Comparison
Compare GEG & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GEG | CLNN |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | 76 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.9M | 69.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GEG | CLNN |
|---|---|---|
| Price | $1.86 | $5.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | ★ 73.9K | 72.2K |
| Earning Date | 05-06-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.20 |
| Revenue Next Year | N/A | $20,465.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $2.28 |
| 52 Week High | $3.51 | $13.50 |
Technical Indicators
Market Signals| Indicator | GEG | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 30.89 | 54.62 |
| Support Level | N/A | $5.59 |
| Resistance Level | $2.19 | $6.88 |
| Average True Range (ATR) | 0.09 | 0.55 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 18.18 | 40.44 |
Price Performance
Historical ComparisonAbout GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.